HOME >> MEDICINE >> NEWS
AstraZeneca announces SYMBICORT is now available in the US

Wilmington, Del. June 25, 2007 -- AstraZeneca announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

Administered twice daily, SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). For many patients, this combination treatment offers improved asthma control as early as day one that is sustained over 12 weeks. SYMBICORT also delivers improved lung function occurring within 15 minutes of beginning treatment. SYMBICORT does not replace fast-acting inhalers for sudden attacks.

SYMBICORT is available in two dose strengths, 80/4.5 and 160/4.5 mcg of budesonide and formoterol, respectively. SYMBICORT is approved for patients whose disease is not adequately controlled on another asthma-controller medication (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

With the U.S. launch of SYMBICORT, millions of asthma sufferers will have a new choice of fixed combination therapy to help achieve control of their asthma, said Chris OBrien, MD, PhD, senior director, Medical Science, AstraZeneca.

Asthma is one of the most serious chronic diseases in the U.S. It is estimated that more than 20 million Americans suffer from the condition and, if not properly managed, asthma can be life-threatening.

The U.S. availability of SYMBICORT holds great promise for millions of Americans that suffer from asthma, said Tony Zook, president and chief executive officer, AstraZeneca U.S. The addition of SYMBICORT to our respiratory portfolio reinforces AstraZenecas commitment to developing new, effective treatments, and provides patients and physicians
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
25-Jun-2007


Page: 1 2

Related medicine news :

1. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
2. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
3. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
4. Weill Cornell Medical College announces gifts totaling $400M
5. GSK announces launch of largest ever Phase III trial in lung cancer treatment
6. Elsevier announces launch of Brain Stimulation
7. NSW Premier announces $15M for childrens cancer research
8. National Inventors Hall of Fame announces 2007 inductees
9. Emory University announces new Global Health Institute
10. BioMed Central announces Journal of Medical Case Reports
11. Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AstraZeneca announces SYMBICORT now available the

(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number ... of the 50 fastest-growing technology companies in the UK. ... five years. Cambrionix Ltd grew 2989 percent during this ... region of Cambridgeshire and East and first in the sector ... is recognition of the hard work put in by our ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dotinga HealthDay Reporter , WEDNESDAY, ... pre-wired to acquire a second language, new research suggests. But ... likely gain a brain boost, the small study finds. ... said study co-author Ping Li, co-director of the Center for ... even more interesting, Li said, that "the brain networks of ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... JOSE, Calif. , Nov. 26, 2014 /PRNewswire/ ... technologies to produce novel therapies for infectious diseases, ... , M.D., an internationally recognized key opinion leader ... the Company,s scientific advisory board. Founder ... Ph.D., stated, "We believe Dr. Opal,s extensive experience ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: